drugset / Trial / NCT01114308
A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction
Phase 3
Completed
287 enrolled
Titan Pharmaceuticals
National Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Probuphine (buprenorphine implant) is an implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This study will confirm the efficacy of Probuphine vs. placebo and compare Probuphine treatment verses treatment with sublingual buprenorphine in the treatment of patients with opioid dependence.
Timeline
- Start
- 2010-04
- Primary completion
- 2011-05
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buprenorphine | Other / unclassified | 12 mg | Subcutaneous |
| Subject | Buprenorphine | Other / unclassified | 16 mg | Subcutaneous |
| Subject | Buprenorphine | Other / unclassified | 80 mg | Subcutaneous |